Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1912 + rituximab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
SHR-A1912 + rituximab + chemotherapy is a combination therapy comprising SHR-A1912 (an anti-CD79b antibody-drug conjugate linked to a DNA topoisomerase I inhibitor), the monoclonal antibody rituximab (targets CD20 on B cells), and various cytotoxic chemotherapy agents. This regimen is being evaluated primarily for B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). SHR-A1912 is developed by Jiangsu HengRui and is designed to deliver potent cytotoxic effects directly to CD79b-expressing malignant B cells. Rituximab depletes B cells by targeting CD20, while the chemotherapy component (regimens such as GemOx or CHOP) offers additional cytotoxicity through diverse mechanisms. The combination aims to increase tumor cell kill rates by leveraging targeted immunotherapy and chemotherapy synergistically[1][3][5][9].
- Other names
- SHR-A1912 + R-Chemo
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAB-cell antigen receptor complex-associated protein beta chainTOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SHR-A1912 + rituximab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1912 + rituximab + chemotherapy.